Molecular characterization of invasive Neisseria meningitidis isolates collected in Lithuania (2009-2019) and estimation of serogroup B meningococcal vaccine 4CMenB and MenB-Fhbp coverage
Neisseria meningitidis causes invasive meningococcal disease (IMD), which is associated with significant mortality and long-term consequences, especially among young children. The incidence of IMD in Lithuania was among the highest in European Union/European Economic Area countries during the past t...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Cellular and Infection Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2023.1136211/full |
| _version_ | 1797924506924220416 |
|---|---|
| author | Emilija Sereikaitė Rūta Plepytė Aurelija Petrutienė Aurelija Petrutienė Dovilė Stravinskienė Indrė Kučinskaitė-Kodzė Vilmantas Gėgžna Inga Ivaškevičienė Inga Ivaškevičienė Aurelija Žvirblienė Milda Plečkaitytė |
| author_facet | Emilija Sereikaitė Rūta Plepytė Aurelija Petrutienė Aurelija Petrutienė Dovilė Stravinskienė Indrė Kučinskaitė-Kodzė Vilmantas Gėgžna Inga Ivaškevičienė Inga Ivaškevičienė Aurelija Žvirblienė Milda Plečkaitytė |
| author_sort | Emilija Sereikaitė |
| collection | DOAJ |
| description | Neisseria meningitidis causes invasive meningococcal disease (IMD), which is associated with significant mortality and long-term consequences, especially among young children. The incidence of IMD in Lithuania was among the highest in European Union/European Economic Area countries during the past two decades; however, the characterization of meningococcal isolates by molecular typing methods has not yet been performed. In this study, we characterized invasive meningococcal isolates (n=294) recovered in Lithuania from 2009 to 2019 by multilocus sequence typing (MLST) and typing of antigens FetA and PorA. The more recent (2017-2019) serogroup B isolates (n=60) were genotyped by analyzing vaccine-related antigens to evaluate their coverage by four-component (4CMenB) and two-component (MenB-Fhbp) vaccines using the genetic Meningococcal Antigen Typing System (gMATS) and Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) Index methods, respectively. The vast majority (90.5%) of isolates belonged to serogroup B. MLST revealed a predominance of clonal complex 32 (74.02%). Serogroup B strain P1.19,15: F4-28: ST-34 (cc32) accounted for 64.1% of IMD isolates. The overall level of strain coverage by the 4MenB vaccine was 94.8% (CI 85.9-98.2%). Most serogroup B isolates (87.9%) were covered by a single vaccine antigen, most commonly Fhbp peptide variant 1 (84.5% of isolates). The Fhbp peptides included in the MenB-Fhbp vaccine were not detected among the analyzed invasive isolates; however, the identified predominant variant 1 was considered cross-reactive. In total, 88.1% (CI 77.5-94.1) of isolates were predicted to be covered by the MenB-Fhbp vaccine. In conclusion, both serogroup B vaccines demonstrate potential to protect against IMD in Lithuania. |
| first_indexed | 2024-04-10T15:02:06Z |
| format | Article |
| id | doaj.art-7e61a2df6b684c6d96b123bb9823aacf |
| institution | Directory Open Access Journal |
| issn | 2235-2988 |
| language | English |
| last_indexed | 2024-04-10T15:02:06Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cellular and Infection Microbiology |
| spelling | doaj.art-7e61a2df6b684c6d96b123bb9823aacf2023-02-15T10:03:23ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882023-02-011310.3389/fcimb.2023.11362111136211Molecular characterization of invasive Neisseria meningitidis isolates collected in Lithuania (2009-2019) and estimation of serogroup B meningococcal vaccine 4CMenB and MenB-Fhbp coverageEmilija Sereikaitė0Rūta Plepytė1Aurelija Petrutienė2Aurelija Petrutienė3Dovilė Stravinskienė4Indrė Kučinskaitė-Kodzė5Vilmantas Gėgžna6Inga Ivaškevičienė7Inga Ivaškevičienė8Aurelija Žvirblienė9Milda Plečkaitytė10Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, LithuaniaInstitute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, LithuaniaInstitute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, LithuaniaDepartment of Bacteriology, National Public Health Surveillance Laboratory, Vilnius, LithuaniaInstitute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, LithuaniaInstitute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, LithuaniaInstitute of Biosciences, Life Sciences Center, Vilnius University, Vilnius, LithuaniaClinic of Children’s Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, LithuaniaPediatric Center, Vilnius University Hospital Santaros Klinikos, Vilnius, LithuaniaInstitute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, LithuaniaInstitute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, LithuaniaNeisseria meningitidis causes invasive meningococcal disease (IMD), which is associated with significant mortality and long-term consequences, especially among young children. The incidence of IMD in Lithuania was among the highest in European Union/European Economic Area countries during the past two decades; however, the characterization of meningococcal isolates by molecular typing methods has not yet been performed. In this study, we characterized invasive meningococcal isolates (n=294) recovered in Lithuania from 2009 to 2019 by multilocus sequence typing (MLST) and typing of antigens FetA and PorA. The more recent (2017-2019) serogroup B isolates (n=60) were genotyped by analyzing vaccine-related antigens to evaluate their coverage by four-component (4CMenB) and two-component (MenB-Fhbp) vaccines using the genetic Meningococcal Antigen Typing System (gMATS) and Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) Index methods, respectively. The vast majority (90.5%) of isolates belonged to serogroup B. MLST revealed a predominance of clonal complex 32 (74.02%). Serogroup B strain P1.19,15: F4-28: ST-34 (cc32) accounted for 64.1% of IMD isolates. The overall level of strain coverage by the 4MenB vaccine was 94.8% (CI 85.9-98.2%). Most serogroup B isolates (87.9%) were covered by a single vaccine antigen, most commonly Fhbp peptide variant 1 (84.5% of isolates). The Fhbp peptides included in the MenB-Fhbp vaccine were not detected among the analyzed invasive isolates; however, the identified predominant variant 1 was considered cross-reactive. In total, 88.1% (CI 77.5-94.1) of isolates were predicted to be covered by the MenB-Fhbp vaccine. In conclusion, both serogroup B vaccines demonstrate potential to protect against IMD in Lithuania.https://www.frontiersin.org/articles/10.3389/fcimb.2023.1136211/fullNeisseria meningitidisserogroup Binvasive meningococcal diseasemultilocus sequence typinggMATSMenDeVAR Index |
| spellingShingle | Emilija Sereikaitė Rūta Plepytė Aurelija Petrutienė Aurelija Petrutienė Dovilė Stravinskienė Indrė Kučinskaitė-Kodzė Vilmantas Gėgžna Inga Ivaškevičienė Inga Ivaškevičienė Aurelija Žvirblienė Milda Plečkaitytė Molecular characterization of invasive Neisseria meningitidis isolates collected in Lithuania (2009-2019) and estimation of serogroup B meningococcal vaccine 4CMenB and MenB-Fhbp coverage Frontiers in Cellular and Infection Microbiology Neisseria meningitidis serogroup B invasive meningococcal disease multilocus sequence typing gMATS MenDeVAR Index |
| title | Molecular characterization of invasive Neisseria meningitidis isolates collected in Lithuania (2009-2019) and estimation of serogroup B meningococcal vaccine 4CMenB and MenB-Fhbp coverage |
| title_full | Molecular characterization of invasive Neisseria meningitidis isolates collected in Lithuania (2009-2019) and estimation of serogroup B meningococcal vaccine 4CMenB and MenB-Fhbp coverage |
| title_fullStr | Molecular characterization of invasive Neisseria meningitidis isolates collected in Lithuania (2009-2019) and estimation of serogroup B meningococcal vaccine 4CMenB and MenB-Fhbp coverage |
| title_full_unstemmed | Molecular characterization of invasive Neisseria meningitidis isolates collected in Lithuania (2009-2019) and estimation of serogroup B meningococcal vaccine 4CMenB and MenB-Fhbp coverage |
| title_short | Molecular characterization of invasive Neisseria meningitidis isolates collected in Lithuania (2009-2019) and estimation of serogroup B meningococcal vaccine 4CMenB and MenB-Fhbp coverage |
| title_sort | molecular characterization of invasive neisseria meningitidis isolates collected in lithuania 2009 2019 and estimation of serogroup b meningococcal vaccine 4cmenb and menb fhbp coverage |
| topic | Neisseria meningitidis serogroup B invasive meningococcal disease multilocus sequence typing gMATS MenDeVAR Index |
| url | https://www.frontiersin.org/articles/10.3389/fcimb.2023.1136211/full |
| work_keys_str_mv | AT emilijasereikaite molecularcharacterizationofinvasiveneisseriameningitidisisolatescollectedinlithuania20092019andestimationofserogroupbmeningococcalvaccine4cmenbandmenbfhbpcoverage AT rutaplepyte molecularcharacterizationofinvasiveneisseriameningitidisisolatescollectedinlithuania20092019andestimationofserogroupbmeningococcalvaccine4cmenbandmenbfhbpcoverage AT aurelijapetrutiene molecularcharacterizationofinvasiveneisseriameningitidisisolatescollectedinlithuania20092019andestimationofserogroupbmeningococcalvaccine4cmenbandmenbfhbpcoverage AT aurelijapetrutiene molecularcharacterizationofinvasiveneisseriameningitidisisolatescollectedinlithuania20092019andestimationofserogroupbmeningococcalvaccine4cmenbandmenbfhbpcoverage AT dovilestravinskiene molecularcharacterizationofinvasiveneisseriameningitidisisolatescollectedinlithuania20092019andestimationofserogroupbmeningococcalvaccine4cmenbandmenbfhbpcoverage AT indrekucinskaitekodze molecularcharacterizationofinvasiveneisseriameningitidisisolatescollectedinlithuania20092019andestimationofserogroupbmeningococcalvaccine4cmenbandmenbfhbpcoverage AT vilmantasgegzna molecularcharacterizationofinvasiveneisseriameningitidisisolatescollectedinlithuania20092019andestimationofserogroupbmeningococcalvaccine4cmenbandmenbfhbpcoverage AT ingaivaskeviciene molecularcharacterizationofinvasiveneisseriameningitidisisolatescollectedinlithuania20092019andestimationofserogroupbmeningococcalvaccine4cmenbandmenbfhbpcoverage AT ingaivaskeviciene molecularcharacterizationofinvasiveneisseriameningitidisisolatescollectedinlithuania20092019andestimationofserogroupbmeningococcalvaccine4cmenbandmenbfhbpcoverage AT aurelijazvirbliene molecularcharacterizationofinvasiveneisseriameningitidisisolatescollectedinlithuania20092019andestimationofserogroupbmeningococcalvaccine4cmenbandmenbfhbpcoverage AT mildapleckaityte molecularcharacterizationofinvasiveneisseriameningitidisisolatescollectedinlithuania20092019andestimationofserogroupbmeningococcalvaccine4cmenbandmenbfhbpcoverage |